Literature DB >> 21562829

Insights from ligand and structure based methods in virtual screening of selective Ni-peptide deformylase inhibitors.

Ravi Shekar Ananthula1, Muttineni Ravikumar, S K Mahmood, M N S Pavan Kumar.   

Abstract

In recent years, there has been a growing interest in developing bacterial peptide deformylase (PDF) inhibitors as novel antibiotics. The purpose of the study is to generate a three-dimensional (3D) pharmacophore model by using diverse PDF inhibitors which is useful for designing of potential antibiotics. Twenty one structurally diverse compounds were considered for the generation of quantitative pharmacophore model using HypoGen of Catalyst, further model was validated using 78 compounds. Pharmacophore model demonstrated the importance of two acceptors, one donor and one hydrophobic feature toward the biological activity. The inhibitors were also docked into the binding site of PDF to comprehend the structural insights of the active site. Combination of ligand and structure based methods were used to find the potential antibiotics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562829     DOI: 10.1007/s00894-011-1068-6

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  33 in total

Review 1.  Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents.

Authors:  C Giglione; M Pierre; T Meinnel
Journal:  Mol Microbiol       Date:  2000-06       Impact factor: 3.501

2.  Peptide deformylase inhibitors with activity against respiratory tract pathogens.

Authors:  Stephen P East; R Paul Beckett; Daniel C Brookings; John M Clements; Sheila Doel; Kenneth Keavey; Gilles Pain; Helen K Smith; Wayne Thomas; Alison J Thompson; Richard S Todd; Mark Whittaker
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

Review 3.  Proteases as drug targets.

Authors:  Andy J Docherty; Tom Crabbe; James P O'Connell; Colin R Groom
Journal:  Biochem Soc Symp       Date:  2003

4.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

5.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

6.  A novel class of inhibitors of peptide deformylase discovered through high-throughput screening and virtual ligand screening.

Authors:  Michael H Howard; Teodorica Cenizal; Steven Gutteridge; Wayne S Hanna; Yong Tao; Maxim Totrov; Vernon A Wittenbach; Ya-Jun Zheng
Journal:  J Med Chem       Date:  2004-12-30       Impact factor: 7.446

7.  Discovery and refinement of a new structural class of potent peptide deformylase inhibitors.

Authors:  Adrien Boularot; Carmela Giglione; Sylvain Petit; Yann Duroc; Rodolphe Alves de Sousa; Valéry Larue; Thierry Cresteil; Frédéric Dardel; Isabelle Artaud; Thierry Meinnel
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

Review 8.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

9.  Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists.

Authors:  Oliver F Funk; Viktor Kettmann; Jan Drimal; Thierry Langer
Journal:  J Med Chem       Date:  2004-05-20       Impact factor: 7.446

10.  Isoxazole-3-hydroxamic acid derivatives as peptide deformylase inhibitors and potential antibacterial agents.

Authors:  Patrizia Calí; Lars Naerum; Seema Mukhija; Anders Hjelmencrantz
Journal:  Bioorg Med Chem Lett       Date:  2004-12-20       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.